TY  - JOUR 
AU  - Ciruelos, E.
AU  - Alba, E.
AU  - López López, Rafael
AU  - Lluch, A.
AU  - Martín, M.
AU  - Arroyo, I.
AU  - Navarro, B.
AU  - Carcedo, D.
AU  - Colomer, R.
AU  - Albanell, J.
PY  - 2019
SN  - 1949-2553
UR  - http://hdl.handle.net/20.500.11940/15408
AB  - Introduction: Trastuzumab has become the standard treatment for both HER2-positive early and metastatic breast cancer (HER2+ eBC or mBC) since its approval. The objective of the study is to estimate the benefit of adjuvant trastuzumab in the treatment...
LA  - eng
TI  - Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval
DO  - 10.18632/oncotarget.27039
T2  - Oncotarget
M2  - 4321
KW  - CHUS
VL  - 10
ER  -